QBiotics’ Stelfonta (tigilanol tiglate) Receives the US FDA’s Approval as the First Treatment for Non-Metastatic MCT in Dogs

November 17, 2020 Auto Bot receives, regulatory, US FDA’s Approval 0

Shots:

  • The approval is based on a study supporting its safety, efficacy in dogs with a measurable cutaneous/ SC MCT on the lower leg and follows the EMA’s MAA granted in early 2020
  • Stelfonta provides 75% complete tumor resolution after just one injection, and dogs quickly regain pre-treatment QoL. The therapy will be launched in the US in the coming months and then made available to primary care veterinarians from early 2021
  • QBiotics is currently investigating Stelfonta in a series of human P-I & P-II clinical trials targeting solid tumors as both as monothx. and an immune checkpoint inhibitor combination therapy

Click here ­to­ read full press release/ article | Ref: QBiotics | Image: iStock

The post QBiotics’ Stelfonta (tigilanol tiglate) Receives the US FDA’s Approval as the First Treatment for Non-Metastatic MCT in Dogs first appeared on PharmaShots.